Knockdown of MicroRNA Let-7a Improves the Functionality of Bone Marrow-Derived Mesenchymal Stem Cells in Immunotherapy

(Molecular Therapy 25, 480–493; February 2017) The authors of this article have reported that some images in Figures 3A, 3D, and 4E have been used in both this article and “Redundant let-7a suppresses the immunomodulatory properties of BMSCs by inhibiting the Fas/FasL system in osteoporosis” (https://doi.org/10.1096/fj.201700885R). An image in Figure 4E was also reused in Figure 6E within the Molecular Therapy article. FASEB is issuing a correction for “Redundant let-7a suppresses the immunomodulatory properties of BMSCs by inhibiting the Fas/FasL system in osteoporosis.” Molecular Therapy has requested all original data for “Knockdown of MicroRNA Let-7a Improves the Functionality of Bone Marrow-Derived Mesenchymal Stem Cells in Immunotherapy” for review. We are publishing this editorial expression of concern while the editors investigate the issues raised by the authors. Knockdown of MicroRNA Let-7a Improves the Functionality of Bone Marrow-Derived Mesenchymal Stem Cells in ImmunotherapyYu et al.Molecular TherapyDecember 11, 2016In BriefKnockdown of let-7a, a conservative miRNA targeting the 3′ UTR of both Fas and FasL mRNA, elevated Fas/FasL protein levels. The increased Fas induced T cell migration, while the increased FasL triggered T cell apoptosis, providing a potential strategy to improve MSC immunotherapy for inflammatory diseases in clinic. Full-Text PDF Open Archive